Biotech company Regeneron (NASDAQ: REGN) will be reporting earnings this Wednesday morning. Here’s what to expect.

Regeneron beat analysts’ revenue expectations last quarter, reporting revenues of $3.88 billion, up 2.5% year on year. It was a very strong quarter for the company, with a solid beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates.

Is Regeneron a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Regeneron’s revenue to grow 14.7% year on year, a reversal from the 3.7% decrease it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Regeneron has missed Wall Street’s revenue estimates multiple times over the last two years.

With Regeneron being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for biotechnology stocks. However, there has been positive investor sentiment in the segment, with share prices up 11% on average over the last month. Regeneron’s stock price was unchanged during the same time .

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.